Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Buy" by Analysts

Key Points

• Arrowhead Pharmaceuticals has received a consensus rating of "Buy" from analysts, with an average 1-year price target of $43.14.
• The company reported a loss of ($1.26) EPS for the last quarter, which was below analysts' expectations, coupled with revenue of $27.77 million.
• Insider transactions revealed that James C. Hamilton sold 15,000 shares at a price of $30.00, reducing his ownership by 6.07%.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has earned a consensus rating of "Buy" from the eight ratings firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $43.1429.

ARWR has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Royal Bank Of Canada reduced their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Finally, Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $29.13 on Thursday. The company's fifty day moving average price is $20.67 and its 200-day moving average price is $16.76. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The firm has a market capitalization of $4.03 billion, a price-to-earnings ratio of -22.76 and a beta of 1.00. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $31.13.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same period in the previous year, the business earned ($1.38) EPS. On average, equities research analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 15,000 shares of the firm's stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $30.00, for a total transaction of $450,000.00. Following the transaction, the insider directly owned 232,122 shares of the company's stock, valued at approximately $6,963,660. This trade represents a 6.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 40,000 shares of company stock worth $1,025,000 in the last ninety days. Corporate insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ARWR. China Universal Asset Management Co. Ltd. increased its stake in Arrowhead Pharmaceuticals by 9.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 27,737 shares of the biotechnology company's stock worth $438,000 after purchasing an additional 2,444 shares during the period. Marex Group plc bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $576,000. State of Wyoming bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $142,000. Hudson Bay Capital Management LP increased its stake in shares of Arrowhead Pharmaceuticals by 22.0% in the second quarter. Hudson Bay Capital Management LP now owns 260,000 shares of the biotechnology company's stock worth $4,108,000 after buying an additional 46,870 shares during the period. Finally, Public Sector Pension Investment Board raised its holdings in Arrowhead Pharmaceuticals by 7.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 428,386 shares of the biotechnology company's stock valued at $6,768,000 after buying an additional 28,516 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.